<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hooper C, Lee YC, Maskell N, BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010. Thorax. 2010 Aug;65(Suppl 2):ii4-17. [163 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20696692&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Maskell NA, Butland RJA, on behalf of the British Thoracic Society Pleural Disease Group, a subgroup of the British Thoracic Society Standards of Care Committee. Thorax 2003;58(Suppl II):ii8-ii17.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: General physical examination  (89.7); Malignant pleural effusion  (511.81); Rheumatoid arthritis  (714.0); Transpleural thoracoscopy  (34.21); Tuberculous pleurisy in primary progressive tuberculosis, unspecified  (010.10); Unspecified pleural effusion  (511.9)"/><FieldValue Value="MSH: Arthritis, Rheumatoid ; Biopsy ; Bronchoscopes ; Bronchoscopy ; Chylothorax ; Connective Tissue Diseases ; Cytological Techniques ; Hematocrit ; Magnetic Resonance Imaging ; Medical History Taking ; Microbiological Techniques ; Natriuretic Peptide, Brain ; Physical Examination ; Pleural Effusion ; Pleural Effusion, Malignant ; Positron-Emission Tomography ; Pulmonary Embolism ; Radiography ; Suction ; Thoracoscopes ; Thoracoscopy ; Tomography Scanners, X-Ray Computed ; Tomography, X-Ray Computed ; Ultrasonography "/><FieldValue Value="MTH: Amylase measurement, pleural fluid ; Aspiration-action ; Biopsy ; Biopsy of pleura (procedure) ; Brain natriuretic peptide measurement ; Chylothorax ; Computed Tomography Scanning Systems ; Connective Tissue Diseases ; Cytological Techniques ; Hematocrit procedure ; Magnetic Resonance Imaging ; Nesiritide ; physical examination ; Pleural effusion disorder ; Pleural fluid protein content measurement ; Positron-Emission Tomography ; Pulmonary Embolism ; Radiographic imaging procedure ; Rheumatoid Arthritis ; Suction drainage ; Thoracoscopy ; Ultrasonography ; X-Ray Computed Tomography "/><FieldValue Value="PDQ: biopsies ; bronchoscopy ; computed tomography ; magnetic resonance imaging ; nesiritide ; ultrasonography "/><FieldValue Value="SNOMEDCT_US: Amylase measurement, pleural fluid  (45516006); Aspiration - action  (129316008); Aspiration - action  (14766002); Benign asbestos pleural effusion  (233639007); Biopsy  (129314006); Biopsy  (86273004); Biopsy of pleura  (116025006); Brain natriuretic peptide measurement  (390917008); Bronchoscope  (24174009); Bronchoscopy  (10847001); Chylothorax  (83035003); Computerized axial tomography  (77477000); Disorder of connective tissue  (105969002); Immunocytochemistry test  (127798001); Immunocytochemistry test  (395126005); Magnetic resonance imaging  (113091000); Magnetic resonance imaging  (312250003); Magnetic resonance imaging unit  (90003000); Neoplastic pleural effusion  (83270006); Nesiritide  (385678006); Nesiritide  (385679003); Nesiritide  (385680000); Nesiritide  (407059007); Packed cell volume measurement  (250231008); Packed cell volume measurement  (28317006); Percutaneous pleural biopsy  (238355009); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Pleural effusion  (60046008); Pleural fluid examination  (167944006); Pleural fluid lactate dehydrogenase measurement  (413050004); Pleural fluid microscopy  (167967008); Pleural fluid pH measurement  (413052007); Pleural fluid protein content measurement  (167961009); Positron emission tomography  (363678002); Positron emission tomography  (82918005); Positron emission tomography unit  (39821008); Positron emission tomography unit  (462323006); Positron emission tomography with computed tomography  (450436003); Pseudochylothorax  (14114003); Pulmonary embolism  (59282003); Quantitative measurement of glucose in pleural fluid specimen  (444128001); Radiographic imaging procedure  (363680008); Rheumatoid arthritis  (69896004); Suction drainage  (274441001); Thoracoscope  (309820007); Thoracoscope  (472817008); Thoracoscopy  (14671001); Thoracoscopy  (359726004); Thoracoscopy  (472818003); Ultrasonography  (16310003); Ultrasonography  (278292003); Ultrasonography  (359659005)"/><FieldValue Value="SPN: BRONCHOSCOPE (FLEXIBLE OR RIGID) ; SYSTEM, IMAGING, PULSED DOPPLER, ULTRASONIC ; SYSTEM, NUCLEAR MAGNETIC RESONANCE IMAGING ; SYSTEM, TOMOGRAPHY, COMPUTED, EMISSION ; SYSTEM, X-RAY, TOMOGRAPHY, COMPUTED "/><FieldValue Value="UMD: Bronchoscopes  (10-491); Procedure Kit/Trays, Biopsy  (10-401); Radiographic Systems  (18-429); Scanning Systems, Computed Tomography  (13-469); Scanning Systems, Computed Tomography/Positron Emission Tomography  (20-161); Scanning Systems, Magnetic Resonance Imaging  (16-260); Scanning Systems, Positron Emission Tomography  (16-375); Scanning Systems, Ultrasonic  (14-278); Thoracoscopes  (14-047)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unilateral pleural effusion&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: The following areas fall outside the scope of this guideline:&lt;/p&gt;&#xD;&#xA;&lt;ul class=&quot;contentListFont&quot;&gt;&#xD;&#xA;    &lt;li&gt;Paediatric pleural disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Detail on thoracic surgical techniques &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of bilateral pleural effusions &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Critical Care" /><FieldValue Value="Geriatrics" /><FieldValue Value="Infectious Diseases" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Oncology" /><FieldValue Value="Pulmonary Medicine" /><FieldValue Value="Radiology" /><FieldValue Value="Thoracic Surgery" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Clinical Laboratory Personnel" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To provide a systematic approach to the investigation of unilateral pulmonary effusion &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To review recent evidence since 2003, allowing new recommendations regarding image guidance of pleural procedures with clear benefits to patient comfort and safety, optimum pleural fluid sampling and processing and the particular value of thoracoscopic pleural biopsies &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To summarise the available evidence to aid the healthcare professional in delivering good quality patient care &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adults with a unilateral pleural effusion&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Clinical assessment and history&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Aspiration &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Drug history &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Initial diagnostic imaging&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Plain radiography &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Ultrasound &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pleural aspiration&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Pleural fluid tests, including protein, lactate dehydrogenase, Gram stain, cytology, and microbiology &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Appearance recorded &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Use of Light's criteria &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Pleural fluid haematocrit &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;N-terminal pro-brain natriuretic peptide (NT-proBNP) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Other tests, including pH, glucose, amylase &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Immunocytochemistry to diagnose malignant effusions &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Further diagnostic imaging&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Computed tomography (CT) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Magnetic resonance imaging (MRI) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Positron emission tomography&amp;ndash;computed tomography (PET-CT) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Invasive investigations&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Percutaneous pleural biopsy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Thoracoscopy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Bronchoscopy &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Specific conditions and tests&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Tuberculous pleurisy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Connective tissue diseases, including rheumatoid arthritis &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Pleural effusions due to pulmonary embolism &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Chylothorax and pseudochylothorax &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Benign asbestos pleural effusion &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of persistent undiagnosed effusions &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Sensitivity and specificity of diagnostic tests &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Correlation of survival and pH in malignant pleural effusion &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Positive and negative likelihood ratios &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Percentage of patients for whom a differential diagnosis is made &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Percentage of patients requiring invasive diagnostic procedures &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Population, Intervention, Comparison, Outcome, and Time (PICOT) Questions&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Guideline members identified and formulated a set of key clinical questions in PICOT format to inform the search strategies for the literature search.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Literature Search&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The British Thoracic Society (BTS) commissioned the Centre for Reviews and Dissemination at the University of York to undertake a bespoke literature search using the search strategies shown in detail on the BTS website (&lt;a href=&quot;http://www.brit-thoracic.org.uk&quot; title=&quot;BTS Website&quot;&gt;http://www.brit-thoracic.org.uk&lt;/a&gt;). The following databases were searched: Ovid MEDLINE (from 1960 onwards) (including MEDLINE In Process), Ovid EMBASE, Cochrane Database of Systematic Reviews (CDRS), the Database of Abstracts of Reviews of Effects (DARE) and the Cochrane Central Register of Controlled Trials. The initial searches were done in June 2008 and revised in September 2009. Searches were limited to English and adult literature; 19,425 potential papers were identified by the search (see online &lt;a href=&quot;http://www.brit-thoracic.org.uk/Portals/0/Guidelines/PleuralDiseaseGuidelines/Pleural%20Guideline%202010/BTS%20Pleural%20disease%202010%20search%20strategy.pdf&quot; title=&quot;BTS Website&quot;&gt;Appendix 1&lt;/a&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Guideline Committee agreed on the following criteria to select relevant abstracts for the guideline:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Studies that addressed the clinical question &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Appropriate study types used to produce the best evidence to answer the clinical question &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Non-English abstracts were not evaluated. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Abstracts were not rejected on the basis of the journal of publication, the country in which the research was done or published or the date of publication. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;A total of 17,393 abstracts were rejected through the criteria outlined above and 2032 full papers were ordered for critical appraisal for the full set of 6 guidelines (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Critical Appraisal of the Literature&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A further 591 full papers were rejected because they fell outside the area of focus and scope of the guideline. Formal critical appraisal to assess the clinical relevance and scientific rigor of 1441 papers was performed independently by at least two guideline reviewers using the Scottish Intercollegiate Guidelines Network (SIGN) critical appraisal checklists (see online &lt;a href=&quot;http://www.brit-thoracic.org.uk/Guidelines/Pleural-Disease-Guidelines-2010.aspx&quot; title=&quot;SIGN Website&quot;&gt;Appendix 2&lt;/a&gt;). The guideline reviewers identified an additional 148 papers during the period of guideline development which were added and critically appraised.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Drafting of the Guideline&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The literature search was repeated by the Centre for Reviews and Dissemination and Centre for Health Economics at the University of York and additional evidence appraised and included in the final draft of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Expert Consensus" /><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Revised Grading System for Recommendations in Evidence Based Guidelines&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; cellpadding=&quot;5&quot; summary=&quot;Table: Revised Grading System for Recommendations in Evidence Based Guidelines&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Evidence&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1++&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High quality meta-analyses, systematic reviews of randomised controlled trials (RCTs), or RCTs with a very low risk of bias&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1+&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1-&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2++&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High quality systematic reviews of case-control or cohort studies &lt;em&gt;or&lt;/em&gt; High quality case-control or cohort studies with a very low risk of confounding, bias or chance and a high probability that the relationship is causal&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2+&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well conducted case-control or cohort studies with a low risk of confounding, bias or chance and a moderate probability that the relationship is causal&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2-&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case-control or cohort studies with a high risk of confounding, bias or chance and a significant risk that the relationship is not causal&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;3&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Non-analytic studies, for example, case reports, case series&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;4&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert opinion&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review with Evidence Tables" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Considered Judgement and Grading of the Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Evidence tables were produced to review the body of evidence and inform the considered judgements and grading of recommendations. Where there was a lack of evidence, consensus statements were derived by incorporating a number of individual non-biased expert opinions from experts in the field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The evidence in each study was graded using the Scottish Intercollegiate Guidelines Network (SIGN) formulated levels of evidence (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Establishment of Guideline Team&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A Working Party was established with representation from a range of professionals with an interest in pleural disease together with a lay representative.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Scope of the Guideline&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The guidelines are based upon the best available evidence. The methodology followed the criteria as set out by the Appraisal of Guidelines Research and Evaluation (AGREE) collaboration in the document the AGREE instrument available online at &lt;a href=&quot;http://www.agreetrust.org&quot; title=&quot;AGREE Website&quot;&gt;http://www.agreetrust.org&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The scope and purpose of the guideline had been agreed and defined in consultation with all potential stakeholders representing the medical and nursing professions, patient groups, health management and industry.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Considered Judgement and Grading of the Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The following were considered in grading of the recommendations:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;The available volume of evidence &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The applicability of the obtained evidence for making recommendations for the defined target audience of this guideline &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;How generalisable the obtained evidence was to the target population for the guideline &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A clear consistency in the evidence obtained to support recommendations &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The implications of recommendations on clinical practice in terms of recourses and skilled expertise. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In-depth cost-effectiveness analysis falls outside the scope of this guideline. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;Recommendations were graded from A+ to D as indicated by the strength of the evidence (see the &quot;Rating Scheme for the Strength of the Recommendations&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Drafting of the Guideline&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Guideline Group produced a draft guideline following regular email consultations and meetings held in December 2007, June 2008, November 2008, February 2009 and May 2009.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Grades of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; cellpadding=&quot;5&quot; summary=&quot;Table: Grades of Recommendations&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Type of Evidence&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At least one meta-analysis, systematic review or randomised controlled trial (RCT) rated as 1++ and directly applicable to the target population &lt;em&gt;or&lt;/em&gt;&lt;br /&gt;&#xD;&#xA;            A systematic review of RCTs or a body of evidence consisting principally of studies rated as 1+ directly applicable to the target population and demonstrating overall consistency of results&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A body of evidence including studies rated as 2++ directly applicable to the target population and demonstrating overall consistency of results &lt;em&gt;or&lt;/em&gt;&lt;br /&gt;&#xD;&#xA;            Extrapolated evidence from studies rated as 1++ or 1+&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A body of evidence including studies rated as 2+ directly applicable to the target population and demonstrating overall consistency of results &lt;em&gt;or&lt;/em&gt;&lt;br /&gt;&#xD;&#xA;            Extrapolated evidence from studies rated as 2++&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence level 3 or 4 &lt;em&gt;or&lt;/em&gt;&lt;br /&gt;&#xD;&#xA;            Extrapolated evidence from studies rated as 2+&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;GPP&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Important practical points for which there is no research evidence nor is there likely to be any research evidence. The Guideline Committee wishes to emphasise these as Good Practice Points.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The draft guideline was available for online public consultation (July/August 2009) and presented to the British Thoracic Society (BTS) Winter Meeting (December 2009). Feedback was invited from a range of stakeholder institutions (see the &quot;Introductions and Methods&quot; section [see the &quot;Availability of Companion Documents&quot; field]). The draft guideline was reviewed by the BTS Standards of Care Committee (September 2009).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The grades of recommendations (&lt;strong&gt;A-D, GPP&lt;/strong&gt;) and levels of evidence (&lt;strong&gt;1++, 1+, 1, 2++, 2+, 2, 3, 4&lt;/strong&gt;) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Note from the British Thoracic Society (BTS) and the National Guideline Clearinghouse (NGC)&lt;/span&gt;&lt;/strong&gt;&lt;/em&gt;: The British Thoracic Society pleural disease guideline 2010 addresses the investigation and medical management of pleural disease in adults and is divided into six sections. In addition to the following summary, please see the following the NGC summaries:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;/content.aspx?id=37611&quot; title=&quot;Guideline #9134&quot;&gt;Management of spontaneous pneumothorax&lt;/a&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;/content.aspx?id=37612&quot; title=&quot;Guideline #9135&quot;&gt;Management of a malignant pleural effusion&lt;/a&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;/content.aspx?id=37613&quot; title=&quot;Guideline #9136&quot;&gt;Management of pleural infection in adults&lt;/a&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;/content.aspx?id=37614&quot; title=&quot;Guideline #9137&quot;&gt;Local anaesthetic thoracoscopy&lt;/a&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;/content.aspx?id=37615&quot; title=&quot;Guideline #9138&quot;&gt;Pleural procedures and thoracic ultrasound&lt;/a&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Clinical Assessment and History&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Aspiration should not be performed for bilateral effusions in a clinical setting strongly suggestive of a transudate unless there are atypical features or they fail to respond to therapy. [&lt;strong&gt;GPP&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;An accurate drug history should be taken during clinical assessment. [&lt;strong&gt;GPP&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Initial Diagnostic Imaging&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Plain Radiography&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Posteroanterior (PA) chest x-rays should be performed in the assessment of suspected pleural effusion. [&lt;strong&gt;GPP&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Ultrasound&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Bedside ultrasound guidance significantly increases the likelihood of successful pleural fluid aspiration and reduces the risk of organ puncture. [&lt;strong&gt;B&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ultrasound detects pleural fluid septations with greater sensitivity than computed tomography (CT). [&lt;strong&gt;C&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Pleural Aspiration&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A diagnostic pleural fluid sample should be aspirated with a fine-bore (21 G) needle and a 50 ml syringe. [&lt;strong&gt;GPP&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Bedside ultrasound guidance improves the success rate and reduces complications (including pneumothorax) and is therefore recommended for diagnostic aspirations. [&lt;strong&gt;B&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pleural fluid should always be sent for protein, lactate dehydrogenase, Gram stain, cytology and microbiological culture. [&lt;strong&gt;C&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Appearance&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The appearance of the pleural fluid and any odour should be recorded. [&lt;strong&gt;GPP&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A pleural fluid haematocrit is helpful in the diagnosis of haemothorax. [&lt;strong&gt;GPP&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Differentiating Between a Pleural Fluid Exudate and Transudate&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Light's criteria should be used to distinguish between a pleural fluid exudate and transudate (see Box 2 in the original guideline document). [&lt;strong&gt;B&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In order to apply Light's criteria, the total protein and lactate dehydrogenase (LDH) should be measured in both blood and pleural fluid. [&lt;strong&gt;B&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Pleural Fluid Differential Cell Counts&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Pleural fluid cell proportions are helpful in narrowing the differential diagnosis but none are disease-specific. [&lt;strong&gt;C&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Any long-standing pleural effusion tends to become populated by lymphocytes. Pleural malignancy, cardiac failure and tuberculosis (TB) are common specific causes of lymphocyte-predominant effusions. [&lt;strong&gt;C&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;pH&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;In non-purulent effusions, when pleural infection is suspected, pleural fluid pH should be measured providing that appropriate collection technique can be observed and a blood gas analyser is available. [&lt;strong&gt;B&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inclusion of air or local anaesthetic in samples may significantly alter the pH results and should be avoided. [&lt;strong&gt;B&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In a parapneumonic effusion, a pH of &amp;lt;7.2 indicates the need for tube drainage. [&lt;strong&gt;B&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Amylase&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Routine measurements of pleural fluid amylase or its isoenzymes are not warranted. It can, however, be useful in suspected cases of oesophageal rupture or effusions associated with pancreatic diseases. [&lt;strong&gt;C&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table: Pleural Fluid Tests and Sample Collection Guidance&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; cellpadding=&quot;5&quot; summary=&quot;Table: Pleural Fluid Tests and Sample Collection Guidance&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Test&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Notes&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Recommended Tests for All Sampled Pleural Effusions&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Biochemistry: LDH and protein &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;2-5 ml in plain container or serum blood collection tube depending on local policy. Blood should be sent simultaneously to biochemistry for total protein and LDH so that Light's criteria can be applied.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Microscopy and culture (MC and S)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;5 ml in plain container. If pleural infection is particularly suspected, a further 5 ml in both anaerobic and aerobic blood culture bottles should be sent&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Cytological examination and differential cell count&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Maximum volume from remaining available sample in a plain universal container. Refrigerate if delay in processing anticipated (e.g., out of hours)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Other Tests Sent Only in Selected Cases as Described in the Original Guideline Document&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;pH&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;In non-purulent effusions when pleural infection is suspected. 0.5-1 ml drawn up into a heparinised blood gas syringe immediately after aspiration. The syringe should be capped to avoid exposure to air. Processed using a ward arterial blood gas machine&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Glucose &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Occasionally useful in diagnosis of rheumatoid effusion. 1-2 ml in fluoride oxalate tube sent to biochemistry&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Acid-fast bacilli and TB culture&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;When there is clinical suspicion of TB pleuritis. Request with MC and S. 5 ml sample in plain container&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Triglycerides and cholesterol&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;To distinguish chylothorax from pseudochylothorax in milky effusions. Can usually be requested with routine biochemistry (LDH, protein) using the same sample&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Amylase&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Occasionally useful in suspected pancreatitis-related effusion. Can usually be requested with routine biochemistry&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Haematocrit &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Diagnosis of haemothorax. 1-2 ml sample in EDTA container sent to haematology&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;EDTA, ethylenediaminetetraacetic acid; LDH, lactate dehydrogenase; TB, tuberculosis&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Cytology&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Malignant effusions can be diagnosed by pleural fluid cytology in about 60% of cases. [&lt;strong&gt;B&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The yield from sending more than two specimens (taken on different occasions) is very low and should be avoided. [&lt;strong&gt;B&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Immunocytochemistry should be used to differentiate between malignant cell types and can be very important in guiding oncological therapy. [&lt;strong&gt;C&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Tumour Markers&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Pleural fluid and serum tumour markers do not currently have a role in the routine investigation of pleural effusions. [&lt;strong&gt;C&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Further Diagnostic Imaging&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Computed Tomography (CT)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;CT scans for pleural effusion should be performed with contrast enhancement of the pleura and before complete drainage of pleural fluid. [&lt;strong&gt;C&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;CT scans should be performed in the investigation of all undiagnosed exudative pleural effusions and can be useful in distinguishing malignant from benign pleural thickening. [&lt;strong&gt;C&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A CT scan should be requested for complicated pleural infection when initial tube drainage has been unsuccessful and surgery is to be considered. [&lt;strong&gt;C&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Invasive Investigations&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Percutaneous Pleural Biopsy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;When investigating an undiagnosed effusion where malignancy is suspected and areas of pleural nodularity are shown on contrast-enhanced CT, an image-guided cutting needle is the percutaneous pleural biopsy method of choice. [&lt;strong&gt;A&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Abrams needle biopsies are only diagnostically useful in areas with a high incidence of TB, although thoracoscopic and image-guided cutting needles have been shown to have a higher diagnostic yield. [&lt;strong&gt;C&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Thoracoscopy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Thoracoscopy is the investigation of choice in exudative pleural effusions where a diagnostic pleural aspiration is inconclusive and malignancy is suspected. [&lt;strong&gt;C&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Bronchoscopy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Routine diagnostic bronchoscopy should not be performed for undiagnosed pleural effusion. [&lt;strong&gt;C&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Bronchoscopy should be considered if there is haemoptysis or clinical or radiographic features suggestive of bronchial obstruction. [&lt;strong&gt;C&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Specific Conditions and Tests&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Tuberculous Pleurisy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;When pleural biopsies are taken, they should be sent for both histological examination and culture to improve the diagnostic sensitivity for TB. [&lt;strong&gt;B&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Thoracoscopic pleural biopsies are the test most likely to yield positive mycobacterial culture (and therefore drug sensitivity) results. [&lt;strong&gt;B&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Surrogate markers of pleural TB are useful 'rule out' tests in low incidence countries. Adenosine deaminase is the most thoroughly validated to date. [&lt;strong&gt;B&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Connective Tissue Diseases&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Rheumatoid Arthritis-Associated Pleural Effusions&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Most chronic pleural effusions secondary to rheumatoid arthritis have a very low glucose level of &amp;lt;1.6 mmol/l (29 mg/dl). [&lt;strong&gt;D&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Systemic Lupus Erythematosus (SLE)&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Pleural fluid antinuclear antibodies should not be measured routinely as it reflects the serum level and is therefore usually unhelpful. [&lt;strong&gt;C&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Chylothorax and Pseudochylothorax&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;If a chylothorax or pseudochylothorax is suspected, pleural fluid should be tested for cholesterol crystals and chylomicrons and the pleural fluid triglyceride and cholesterol levels measured. [&lt;strong&gt;C&lt;/strong&gt;] &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grades of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; cellpadding=&quot;5&quot; summary=&quot;Table: Grades of Recommendations&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Type of Evidence&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At least one meta-analysis, systematic review or randomised controlled trial (RCT) rated as 1++ and directly applicable to the target population &lt;em&gt;or&lt;/em&gt;&lt;br /&gt;&#xD;&#xA;            A systematic review of RCTs or a body of evidence consisting principally of studies rated as 1+ directly applicable to the target population and demonstrating overall consistency of results&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A body of evidence including studies rated as 2++ directly applicable to the target population and demonstrating overall consistency of results &lt;em&gt;or&lt;/em&gt;&lt;br /&gt;&#xD;&#xA;            Extrapolated evidence from studies rated as 1++ or 1+&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A body of evidence including studies rated as 2+ directly applicable to the target population and demonstrating overall consistency of results &lt;em&gt;or&lt;/em&gt;&lt;br /&gt;&#xD;&#xA;            Extrapolated evidence from studies rated as 2++&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence level 3 or 4 &lt;em&gt;or&lt;/em&gt;&lt;br /&gt;&#xD;&#xA;            Extrapolated evidence from studies rated as 2+&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;GPP&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Important practical points for which there is no research evidence nor is there likely to be any research evidence. The Guideline Committee wishes to emphasise these as Good Practice Points.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Revised Grading System for Recommendations in Evidence Based Guidelines&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; cellpadding=&quot;5&quot; summary=&quot;Table: Revised Grading System for Recommendations in Evidence Based Guidelines&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Evidence&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1++&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High quality meta-analyses, systematic reviews of randomised controlled trials (RCTs), or RCTs with a very low risk of bias&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1+&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1-&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2++&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High quality systematic reviews of case-control or cohort studies &lt;em&gt;or&lt;/em&gt; High quality case-control or cohort studies with a very low risk of confounding, bias or chance and a high probability that the relationship is causal&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2+&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well conducted case-control or cohort studies with a low risk of confounding, bias or chance and a moderate probability that the relationship is causal&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2-&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case-control or cohort studies with a high risk of confounding, bias or chance and a significant risk that the relationship is not causal&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;3&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Non-analytic studies, for example, case reports, case series&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;4&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert opinion&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An algorithm for the investigation of a unilateral pleural effusion is provided in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Establishment of a diagnosis swiftly while minimising unnecessary invasive investigations and facilitating treatment, avoiding the need for repeated therapeutic aspirations when possible&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Complications from invasive procedures &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In one series of 566 examinations, the most common side effect of video-assisted thoracoscopic surgery (VATS) was subcutaneous emphysema with cardiac dysrhythmia and air embolism occurring in &amp;lt;1% and no deaths. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Clinical Algorithm" /><FieldValue Value="Quick Reference Guides/Physician Guides" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hooper C, Lee YC, Maskell N, BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010. Thorax. 2010 Aug;65(Suppl 2):ii4-17. [163 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20696692&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2003 (revised 2010 Aug)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="British Thoracic Society - Medical Specialty Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;British Thoracic Society&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;British Thoracic Society Pleural Guideline Group&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Guideline Group Members&lt;/em&gt;: Clare Hooper, Southmead Hospital, Bristol, UK; Y C Gary Lee, Lung Institute of Western Australia, University Dept Med, Perth, Western Australia, Australia; Nick Maskell, Department of Clinical Sciences, Southmead Hospital, University of Bristol, Bristol, UK&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;No member of the Guideline Group is aware of any competing interests.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Maskell NA, Butland RJA, on behalf of the British Thoracic Society Pleural Disease Group, a subgroup of the British Thoracic Society Standards of Care Committee. Thorax 2003;58(Suppl II):ii8-ii17.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;https://www.brit-thoracic.org.uk/guidelines-and-quality-standards/pleural-disease-guideline/&quot; title=&quot;British Thoracic Society (BTS) Web site&quot;&gt;British Thoracic Society (BTS) Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;BTS pleural disease guideline 2010. A quick reference guide. London (UK): British Thoracic Society; 2010. 15 p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;https://www.brit-thoracic.org.uk/document-library/clinical-information/pleural-disease/pleural-disease-guidelines-2010/pleural-disease-guideline-quick-reference-guide/&quot; title=&quot;BTS Web site&quot;&gt;British Thoracic Society (BTS) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Introduction and methods: British Thoracic Society pleural disease guideline 2010. Thorax 2010;65(Suppl 2):ii1-ii3. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.brit-thoracic.org.uk/Portals/0/Guidelines/PleuralDiseaseGuidelines/Pleural%20Guideline%202010/Pleural%20disease%202010%20Introduction.pdf&quot; title=&quot;BTS Web site&quot;&gt;BTS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Online appendix 1. Search strategy. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.brit-thoracic.org.uk/Portals/0/Guidelines/PleuralDiseaseGuidelines/Pleural%20Guideline%202010/BTS%20Pleural%20disease%202010%20search%20strategy.pdf&quot; title=&quot;BTS Web site&quot;&gt;BTS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Online appendix 2. Link to SIGN critical appraisal checklists. Available from the &lt;a href=&quot;http://www.brit-thoracic.org.uk/Guidelines/Pleural-Disease-Guidelines-2010.aspx&quot; title=&quot;BTS Web site&quot;&gt;BTS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Investigation of a unilateral pleural effusion in adults &amp;ndash; British Thoracic Society pleural disease guideline 2010. Evidence tables. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.brit-thoracic.org.uk/Portals/0/Guidelines/PleuralDiseaseGuidelines/Pleural%20Guideline%202010/Investigation%20section%20final%20evidence%20tables%20A%20B%20C%20July%202010.pdf&quot; title=&quot;BTS Web site&quot;&gt;BTS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on August 17, 2012. The information was verified by the guideline developer on October 26, 2012.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
